Alfasigma Denmark ApS: Financial statements 2023
CVR: 42447242
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
Alfasigma Denmark ApS (CVR 42447242) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK 11,777,533 and a net result of DKK 1,389,584 compared with DKK 1,445,936 the year before. That is a decrease of 14.7% compared with the year before. Equity in the 2023 report amounted to DKK 3,273,771. The solvency ratio was 44.9%. The company had 6 employees in the financial year.
- Gross Profit
- DKK 11,777,533
- Profit/Loss
- DKK 1,389,584
- Equity
- DKK 3,273,771
- Total Assets
- DKK 7,284,274
- Employees
- 6
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | 11.8 mio. | 1.4 mio. | 3.3 mio. | 6 |
| 2022 | - | 13.8 mio. | 1.4 mio. | 1.9 mio. | 6 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
Alfasigma Denmark ApS has published its annual report for 2022. Gross profit came to DKK 13,808,766, and the net result was DKK 1,445,936.
As of June 20, 2023, Bart Filius has stepped down as director of Alfasigma Denmark ApS.
About Alfasigma Denmark ApS
Alfasigma Denmark ApS is a Danish company of the type Anpartsselskab based in København Ø, founded in 2021. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named Galapagos Biopharma Denmark ApS. The management consists of Alberto Avaltroni, Alessio Battaglia and Line de Linde Henriksen. The company is owned by ALFASIGMA SpA. The company has 6 employees (2026). In 2025, the company reported a gross profit of DKK 10,680,660 and a net result of DKK 505,448 compared with DKK 815,009 the year before. Equity in the 2025 report amounted to DKK 4,594,228.